VERO Biotech Inc., a fast-growing commercial business dedicated to improving the lives of patients through innovative technologies, today announced the funding of up to $100 million in a Series E financing round led by MVM Partners (MVM), which included participation from a strategic investor.  Funds from the round will support the expanded commercialization of the GENOSYL® Delivery System (GENOSYL® DS).

GENOSYL® DS is the first and only tankless inhaled nitric oxide (NO) delivery system approved by the U.S. Food and Drug Administration (FDA). NO dilates blood vessels to treat severe pulmonary hypertension, a life-threatening condition that can occur in neonates and patients with respiratory distress. Unlike tank-based systems, GENOSYL® DS generates NO at the bedside using a small disposable cassette. This eliminates the need for hospitals to manage bulky tanks and helps to simplify clinical workflow.

“As MVM is committed to supporting the growth of companies with innovative technologies to treat unmet medical needs, it was clear MVM is the right fit for our next stage of growth,” said Brent V. Furse, CEO and President, VERO Biotech. “MVM has a deep understanding of our business, and we will be able to leverage MVM’s experience in bringing innovative products to market, driving growth, making strategic acquisitions, and establishing new standards of care in medicine. VERO’s partnership with MVM will ensure greater access to our proprietary tankless, cassette-based GENOSYL Delivery System.”

Eric Bednarski, Partner of MVM commented: “VERO Biotech has a best-in-class technology that improves the clinical care of patients requiring inhaled nitric oxide therapy. GENOSYL has gained significant market traction with adoption by some of the top hospitals in the US. We are extremely impressed by the management team and excited to partner with VERO Biotech to help the company achieve its near- and long-term goals.”

About VERO Biotech

VERO Biotech Inc. (formerly known as GeNO LLC) is focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases.

VERO Biotech is dedicated to improving the lives of patients by leading the development of innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever inhaled nitric oxide treatment is needed.